If you're looking to bolster your portfolio with some blue chip shares in August, you may want to look at the two listed below.
Here's why these blue chip ASX shares are highly rated right now:
Healius Ltd (ASX: HLS)
The first blue chip ASX 200 share to look at is Healius. It is one of Australia's largest pathology and diagnostic imaging providers and the name behind a number of brands including Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.
Healius has been growing at a very strong rate over the last couple of years thanks to huge demand for COVID testing. And while testing volumes are falling, the team at Morgans remain positive on the company. This is due to its belief that Healius' base business will rebound as COVID headwinds ease.
Morgans has an add rating and $4.30 price target on Healius' shares.
REA Group Limited (ASX: REA)
Another ASX blue chip ASX 200 share that could be in the buy zone is REA Group. It is a leading online provider of property and property-related services across Australia and Asia.
The company's realestate.com.au website has been dominating the ANZ market for years and shows no signs of stopping. For example, during the first half of FY 2022, REA reported an average of 12.6 million unique visitors to its website each month. Furthermore, on average, there were 3.3x more visits than the nearest competitor each month.
And combined with its strong pricing power and new acquisitions and revenue streams, the company has been tipped to continue growing at a solid rate for many years to come by the team at Goldman Sachs.
In light of this, the broker currently has a buy rating and $164.00 price target on REA's shares.
